A Multi-Center, Open-Label, Dose-Titration Pilot Study Evaluating the Efficacy and Safety of Oxybutynin Transdermal Systems in Patients With Neurogenic Bladder Resulting From Spinal Cord Injury.
Phase of Trial: Phase IV
Latest Information Update: 17 Jan 2013
At a glance
- Drugs Oxybutynin (Primary)
- Indications Overactive bladder
- Focus Therapeutic Use
- Sponsors Actavis Inc
- 04 May 2010 Actual patient number (24) added as reported by ClinicalTrials.gov.
- 06 Feb 2010 New trial record